Moleculin Biotech has dosed the first subjects in the Phase II portion of a Phase Ib/II trial evaluating the company’s anthracycline candidate in combination with Cytarabine (Ara-C) for the treatment of acute myeloid leukaemia.
The study (NCT05319587) is a multicentre, open-label, dose-escalation trial evaluating safety and dosage data of the company’s candidate Annamycin. Moleculin has already successfully conducted two single-agent trials with Annamycin in the US and Europe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In July 2023, the Houston, US-based pharma company announced positive results from the European study. The data, which was published in the British Journal of Cancer Research, demonstrated a safe and efficacious dose of 230 mg/m2. The same dose is being used in the Phase II portion.
Patients will receive a two-hour intravenous (IV) infusion of liposomal Annamycin daily for three consecutive days followed by 18 days off the drug, for a treatment cycle time of 21 days. Cytarabine, a standard chemotherapy drug, will also be administered at a dose of 2.0 g/m2 per day for hours by IV infusion for 5 consecutive days.
In December 2020, the US Food and Drug Administration (FDA) granted orphan drug designation to Annamycin for soft tissue sarcoma lung metastases. A Fast Track designation followed in March 2021. Moleculin recently completed enrolment in a trial of the candidate for STS lung metastases treatment.
Moleculin chairman and CEO Walter Klemp said: “Based on the positive preliminary results demonstrated in the Phase Ib portion of this trial, we continue to believe that Annamycin has the potential to be a meaningful treatment option for the treatment of AML.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
